Retraction: Ke et al. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. Frontiers in Bioscience (Landmark Edition). 2019; 24: 1452–1461

The Editor-in-Chief has retracted the article entitled “Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel” [1] due to significant concerns regarding the reliability and integrity of the data presented.

Recently, several issues were brought to the attention of the Publisher and Editor-in-Chief regarding the originality and authenticity of the images in this paper published in 2019 prior to the present publisher and EiC taking over the management of the journal. The content of repeated figures includes but is not limited to:

(1) Fig. 1C contains images that are identical to those in Fig. 4A of a previously published paper [2].

(2) Fig. 3A contains images that are identical to those in Fig. 5F of a previously published paper [3].

These duplications of images raise serious questions about the validity of the results and the adherence to ethical standards of research. The authors were contacted for an explanation but did not reply. Therefore, the Editor-in-Chief no longer has confidence in the research presented in this work and retracted the article.

References

[1] Jie KY, Wei CL, Min Z, Ping GJ, Ying W, Dan Z, et al. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. Frontiers in Bioscience (Landmark Edition). 2019; 24: 1452–1461. https://doi.org/10.2741/4790.

[2] Gao H, Peng L, Li C, Ji Q, Li P. Salidroside Alleviates Cartilage Degeneration Through NF-κB Pathway in Osteoarthritis Rats. Drug Design, Development and Therapy. 2020; 14: 1445–1454. https://doi.org/10.2147/DDDT.S242862.

[3] Xu G, Meng L, Yuan D, Li K, Zhang Y, Dang C, et al. MEG3/miR 21 axis affects cell mobility by suppressing epithelial mesenchymal transition in gastric cancer. Oncology Reports. 2018; 40: 39–48. https://doi.org/10.3892/or.2018.6424.